Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Abcellera Biologics Inc
(NQ:
ABCL
)
2.570
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Abcellera Biologics Inc
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Micro/Small Cap Companies Using AI In Drug Discovery Up 35% In November
December 06, 2023
The AI method is up to 250 times more efficient than the traditional method of drug discovery. reducing timelines for drug discovery, increasing accuracy of efficacy and safety predictions.
Via
Talk Markets
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
AbCellera to Present at the Piper Sandler 35th Annual Healthcare Conference on November 30, 2023
November 16, 2023
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Presents New Data on Two T-Cell Engager Programs at SITC 2023
November 03, 2023
From
AbCellera Biologics Inc.
Via
Business Wire
Earnings Preview: AbCellera Biologics
August 02, 2023
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
November 03, 2023
Via
Benzinga
AbCellera Biologics (ABCL) Q3 2023 Earnings Call Transcript
November 03, 2023
ABCL earnings call for the period ending September 30, 2023.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
12 Health Care Stocks Moving In Thursday's After-Market Session
November 02, 2023
Via
Benzinga
AbCellera Reports Q3 2023 Business Results
November 02, 2023
From
AbCellera Biologics Inc.
Via
Business Wire
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
November 01, 2023
From
AbCellera Biologics Inc.
Via
Business Wire
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
November 01, 2023
Multi-year collaboration to jointly discover, develop, and commercialize novel oncology medicines for up to five programs, with the first ADC program focusing on a SMARCA degrader
From
Prelude Therapeutics, Inc.; AbCellera
Via
GlobeNewswire
AbCellera to Present at the Jefferies London Healthcare Conference on November 14, 2023
October 31, 2023
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera to Report Third Quarter 2023 Financial Results on November 2, 2023
October 11, 2023
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Announces Two T-Cell Engager Presentations at SITC 2023
September 27, 2023
From
AbCellera Biologics Inc.
Via
Business Wire
Argenx's 28% Surge & Promising Product Propel Investor Confidence
September 25, 2023
Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.
Via
MarketBeat
AbCellera Expands Multi-Target Antibody Discovery Collaboration with Regeneron
September 20, 2023
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Announces Collaboration with Incyte to Accelerate the Discovery and Development of Therapeutic Antibodies in Oncology
September 13, 2023
From
AbCellera Biologics Inc.
Via
Business Wire
Why AbCellera Biologics Is Still A Buy Despite Dropping Royalties: Analyst On Long-Term Prospects
August 31, 2023
Benchmark analyst Robert Wasserman reiterated a Buy rating on AbCellera Biologics Inc. (NASDAQ: ABCL),
Via
Benzinga
3 AI Stocks You’ll Regret Not Buying Soon
August 08, 2023
AI will have a big impact on biotech, which could help with drug discovery and create opportunities for these top AI stocks to invest in.
Via
InvestorPlace
Why ResMed Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session
August 04, 2023
Gainers Missfresh Limited (NASDAQ: MF) jumped 168% to $1.38 after the company announced entry of share purchase agreements for financing and business acquisition.
Via
Benzinga
Apple, Fortinet, Microchip Technology And Other Big Stocks Moving Lower In Friday's Pre-Market Session
August 04, 2023
U.S. stock futures traded higher this morning on Friday. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
AbCellera Biologics (ABCL) Q2 2023 Earnings Call Transcript
August 04, 2023
ABCL earnings call for the period ending June 30, 2023.
Via
The Motley Fool
12 Health Care Stocks Moving In Thursday's After-Market Session
August 03, 2023
Via
Benzinga
AbCellera Reports Q2 2023 Business Results
August 03, 2023
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Announces that the U.S. Patent Trial and Appeal Board Has Denied Berkeley Lights’ Request for Rehearing
July 24, 2023
From
AbCellera Biologics Inc.
Via
Business Wire
Why Lucid Group Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
July 12, 2023
Gainers Healthcare Triangle, Inc. (NASDAQ: HCTI) shares climbed 171.2% to $8.84 as the company launched initiative to prevent ransomware attacks in the $35 billion healthcare data market.
Via
Benzinga
InMode, Daktronics, Domino's Pizza And Other Big Stocks Moving Higher On Wednesday
July 12, 2023
U.S. stocks traded higher, with the Dow Jones gaining around 250 points on Wednesday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Looking for Biotech AI Stocks? 3 Names That Will Benefit From the AI Boom
July 08, 2023
AI is changing the face of biotechnology and drug discovery. Don't miss out on the next big boom in biotech, here are 3 stocks to consider.
Via
InvestorPlace
AbCellera to Report Second Quarter 2023 Financial Results on August 3, 2023
July 06, 2023
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera to Present at the Goldman Sachs 44th Annual Global Healthcare Conference on June 13, 2023
May 29, 2023
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Partners with the Governments of Canada and British Columbia to Advance Drug Development Capabilities and Infrastructure that Will Accelerate Innovative Medicines to Patients
May 24, 2023
From
AbCellera Biologics Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.